Daré Bioscience (DARE) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
27 Oct, 2026Executive summary
Stockholders were urged to submit votes before the November 10, 2026 special meeting so ballots could be tabulated in advance.
Voting matters and shareholder proposals
Proposals were presented for a vote at the special meeting; the reminder did not specify their substance.
Voting options included telephone, online, or returning the enclosed voting form; stockholders with shares in multiple accounts were asked to vote each account.
Morrow Sodali LLC was available for voting assistance Monday through Saturday, 9 a.m.–9 p.m. Eastern Time, at 1-888-777-2094.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Daré Bioscience
- Two launches lead a grant-backed pipeline spanning contraception, sexual health and menopause.DARE
Corporate presentation - Commercial launches advance as Ovaprene and DARE-HPV data approach in 2027.DAREStifel 2026 Healthcare Conference 2026
- Stockholders approved the warrant-share issuance proposal and conditional adjournment.DAREEGM 2026
- Warrant approval could enable 8.9 million shares, with potential 45.4% dilution.DAREProxy filing
- Approval sought for warrant-related share issuance that could dilute ownership by up to 45%.DAREProxy filing
- Launching two women's health products in 2026, backed by $75M+ in funding and late-stage pipeline.DARECorporate presentation
- Commercial launches and late-stage clinical milestones mark a pivotal year for women's health innovation.DAREH.C. Wainwright 28th Annual Global Investment Conference
- Women's health biotech pursues dual-path market strategy amid financial and listing risks.DARERegistration filing
- New product launches and key clinical milestones drive a pivotal growth phase.DAREInvestor update